BeauBrain Healthcare

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Request demo

BeauBrain Healthcare - overview

About

Based in Seoul, South Korea, and founded in 2022 by its CEO Sangwon Seo, and co-founders Na Deok-real, BeauBrain Healthcare operates as a healthcare company that develops brain analysis solutions to diagnose and prevent dementia. In December 2023, BeauBrain Healthcare raised KRW 3 billion in pre-series A funding from Daewoong Pharmaceutical, Lotte Ventures, Tail Ventures, and Korea Technology Finance Corporation. BeauBrain Healthcare offers a range of solutions for early prediction of ATN biomarkers (Amyloid Beta, Tau, Neurodegeneration) associated with Alzheimer’s. Additionally, the company provides personalized cognitive training programs (digital therapeutics) designed for prevention and treatment.

By amalgamating accumulated ATN biomarker data and cognitive function data with Asia's genetic data, BeauBrain aims to implement precision medicine in its pursuit of freeing individuals from the clutches of dementia.

Current Investors

Korea Technology Finance Corporation, Lotte Ventures, Daewoong Pharmaceutical

Request a demo

Primary Industry

Healthcare Specialists

Sub Industries

Healthcare Specialists, Diagnostic Equipment

Website

www.beaubrain.bio

Verticals

HealthTech

Company Stage

Angel & Seed

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.

Request demo